- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
FDA approves Genmab’s ofatumumab for relapsed CLL
31 August 2016 • Author: Niamh Louise Marriott, Digital Content Producer
The US Food and Drug Administration (FDA) has approved Genmab’s ofatumumab (Arzerra), in combination with fludarabine and cyclophosphamide (FC), to treat patients with relapsed chronic lymphocytic leukaemia (CLL).
Approval for this indication by the FDA is based on results from the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL.
Ofatumumab is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of chronic lymphocytic leukaemia (CLL) cells and normal B lymphocytes.
The evidentiary trial
The Phase III study examined 365 patients in 18 countries with relapsed CLL, randomising them 1:1 to treatment with up to six cycles of ofatumumab in combination with fludarabine and cyclophosphamide (FC) or up to six cycles with fludarabine and cyclophosphamide alone.
The primary endpoint of the study was progression free survival (PFS).
A median PFS in patients receiving the combined drugs was 28.9 months, compared to 18.8 months in patients receiving FC alone (HR =0.67, p=0.0032).
Secondary endpoints included overall response rate, overall survival, patient reported outcomes, time to response, duration of response, time to progression, time to next therapy, safety assessments and quality of life. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed.
“This is the fourth CLL indication approved in the US for arzerra, and we are pleased to see the availability of this treatment expand to a wider number of patients,” said Jan van de Winkel, PhD Chief Executive Officer of Genmab.
Chronic lymphocytic leukaemia
CLL is the most commonly diagnosed adult leukaemia in Western countries, and accounts for approximately 1 in 4 cases of leukaemia. Most CLL patients experience disease progression despite initial response to therapy and may require additional treatment.
The application was submitted to the FDA by Novartis under the ofatumumab collaboration between Novartis and Genmab.
Arzerra is marketed under a collaboration agreement between Genmab and Novartis. Novartis has rights to develop ofatumumab in autoimmune indications, including multiple sclerosis.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics